.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Fish and Richardson
Citi
Express Scripts
Cipla
Accenture
Baxter
McKinsey
Farmers Insurance
US Army

Generated: December 13, 2017

DrugPatentWatch Database Preview

Details for Patent: 7,807,689

« Back to Dashboard

Which drugs does patent 7,807,689 protect, and when does it expire?


Patent 7,807,689 protects KAZANO, NESINA, and OSENI, and is included in three NDAs. There have been zero Paragraph IV challenges on Nesina and Kazano

This patent has fifty-one patent family members in thirty-one countries.

Summary for Patent: 7,807,689

Title:Dipeptidyl peptidase inhibitors
Abstract: The present invention provides a compound of the formula: ##STR00001## or stereoisomers or pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, articles of manufacture comprising the same, and methods of using the same.
Inventor(s): Zhang; Zhiyuan (San Diego, CA), Elder; Bruce J. (Wynantskill, NY), Isbester; Paul K. (Castleton, NY), Palmer; Grant J. (Clifton Park, NY), Ulysse; Luckner G. (Albany, NY)
Assignee: Takeda Pharmaceutical Company Limited (Osaka, JP)
Application Number:11/080,992
Patent Claim Types:
see list of patent claims
Compound; Composition; Formulation; Dosage form; Delivery; Use;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Patented / Exclusive Use
Takeda Pharms UsaKAZANOalogliptin benzoate; metformin hydrochlorideTABLET;ORAL203414-002Jan 25, 2013RXYesYes► Subscribe► Subscribe► SubscribeYYMETHOD OF TREATING DIABETES COMPRISING ADMINISTERING ALOGLIPTIN
Takeda Pharms UsaKAZANOalogliptin benzoate; metformin hydrochlorideTABLET;ORAL203414-001Jan 25, 2013RXYesNo► Subscribe► Subscribe► SubscribeYYMETHOD OF TREATING DIABETES COMPRISING ADMINISTERING ALOGLIPTIN
Takeda Pharms UsaNESINAalogliptin benzoateTABLET;ORAL022271-001Jan 25, 2013RXYesNo► Subscribe► Subscribe► SubscribeYYMETHOD OF TREATING DIABETES COMPRISING ADMINISTERING ALOGLIPTIN
Takeda Pharms UsaNESINAalogliptin benzoateTABLET;ORAL022271-002Jan 25, 2013RXYesNo► Subscribe► Subscribe► SubscribeYYMETHOD OF TREATING DIABETES COMPRISING ADMINISTERING ALOGLIPTIN
Takeda Pharms UsaNESINAalogliptin benzoateTABLET;ORAL022271-003Jan 25, 2013RXYesYes► Subscribe► Subscribe► SubscribeYYMETHOD OF TREATING DIABETES COMPRISING ADMINISTERING ALOGLIPTIN
Takeda Pharms UsaOSENIalogliptin benzoate; pioglitazone hydrochlorideTABLET;ORAL022426-004Jan 25, 2013RXYesNo► Subscribe► Subscribe► SubscribeYYMETHOD OF TREATING DIABETES COMPRISING ADMINISTERING ALOGLIPTIN
Takeda Pharms UsaOSENIalogliptin benzoate; pioglitazone hydrochlorideTABLET;ORAL022426-005Jan 25, 2013RXYesNo► Subscribe► Subscribe► SubscribeYYMETHOD OF TREATING DIABETES COMPRISING ADMINISTERING ALOGLIPTIN
Takeda Pharms UsaOSENIalogliptin benzoate; pioglitazone hydrochlorideTABLET;ORAL022426-006Jan 25, 2013RXYesNo► Subscribe► Subscribe► SubscribeYYMETHOD OF TREATING DIABETES COMPRISING ADMINISTERING ALOGLIPTIN
Takeda Pharms UsaOSENIalogliptin benzoate; pioglitazone hydrochlorideTABLET;ORAL022426-001Jan 25, 2013RXYesNo► Subscribe► Subscribe► SubscribeYYMETHOD OF TREATING DIABETES COMPRISING ADMINISTERING ALOGLIPTIN
Takeda Pharms UsaOSENIalogliptin benzoate; pioglitazone hydrochlorideTABLET;ORAL022426-002Jan 25, 2013RXYesNo► Subscribe► Subscribe► SubscribeYYMETHOD OF TREATING DIABETES COMPRISING ADMINISTERING ALOGLIPTIN
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 7,807,689

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,329,900Dipeptidyl peptidase inhibitors► Subscribe
7,781,584Dipeptidyl peptidase inhibitors► Subscribe
8,288,539Dipeptidyl peptidase inhibitors► Subscribe
8,173,663Dipeptidyl peptidase inhibitors► Subscribe
8,188,275Dipeptidyl peptidase inhibitors► Subscribe
7,906,523Dipeptidyl peptidase inhibitors► Subscribe
7,795,428Dipeptidyl peptidase inhibitors► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 7,807,689

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Denmark1586571► Subscribe
China102127053► Subscribe
China102127057► Subscribe
China102134229► Subscribe
China102134230► Subscribe
China102134231► Subscribe
China102140090► Subscribe
Costa Rica8595► Subscribe
Cyprus1108393► Subscribe
Germany602004015067► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Citi
Novartis
Federal Trade Commission
Express Scripts
Colorcon
Cipla
Merck
Julphar
Harvard Business School
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot